Cell therapy (CAR-T) · developed by Janssen Research & Development, LLC
Phase 1/2Most advanced trial (none active)
1Registered trials
What is LCAR-B38M?
LCAR-B38M is a CAR-T cell injection, a patient's own T cells engineered to express a chimeric antigen receptor. It is studied in refractory or relapsed multiple myeloma.
Summary written with AI from the sources listed at the end of this page.
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Conditions studied
Refractory or Relapsed Multiple Myeloma
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.